In addition, the limited response to anti-PD1 treatment demonstrates the potential for utilizing this preclinical model to study the mechanisms of limited immunotherapy response in cSCC, a population that continues to require more treatment options. Here, PDCD1 is linked to skin squamous cell carcinoma.